Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.

Pellicelli A, Messina V, Giannelli V, Distefano M, Palitti VP, Vignally P, Tarquini P, Izzi A, Moretti A, Babudieri S, Dell'Isola S, Marignani M, Scifo G, Iovinella V, Cariti G, Pompili M, Candilo FD, Fontanella L, Ettorre GM, Vennarecci G, Ippolito AM, Barbarini G; Working Group CLEO.

Gut Liver. 2019 Aug 14. doi: 10.5009/gnl18269. [Epub ahead of print]

2.

Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.

Osman GA, Marra A, Iacono D, Giannelli V, Ricciardi S, Remotti D, Vecchione A, Ricci A, Palange P, Migliorino MR.

Anticancer Drugs. 2019 Aug;30(7):e0764. doi: 10.1097/CAD.0000000000000764.

PMID:
30950836
3.

Congenital extrahepatic portosystemic shunt: description of four cases and review of the literature.

Ponziani FR, Faccia M, Zocco MA, Giannelli V, Pellicelli A, Ettorre GM, De Matthaeis N, Pizzolante F, De Gaetano AM, Riccardi L, Pompili M, Rapaccini GL.

J Ultrasound. 2019 Sep;22(3):349-358. doi: 10.1007/s40477-018-0329-y. Epub 2018 Oct 24. Review.

PMID:
30357760
4.

Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma.

Pellicelli A, Giannelli V, Zoli V, Pellicelli V, Zignego AL.

Clin Exp Hepatol. 2018 Sep;4(3):197-200. doi: 10.5114/ceh.2018.78124. Epub 2018 May 10.

5.

Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.

Masetti C, Lionetti R, Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'Unto C, Francioso S, Brega A, Montalbano M, Visco-Comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'Offizi G, Gasbarrini A, De Santis A, Angelico M.

J Viral Hepat. 2018 Dec;25(12):1493-1500. doi: 10.1111/jvh.12982. Epub 2018 Sep 6.

PMID:
30112854
6.

Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy.

Iebba V, Guerrieri F, Di Gregorio V, Levrero M, Gagliardi A, Santangelo F, Sobolev AP, Circi S, Giannelli V, Mannina L, Schippa S, Merli M.

Sci Rep. 2018 May 29;8(1):8210. doi: 10.1038/s41598-018-26509-y.

7.

Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study.

Vespasiani-Gentilucci U, Dell'Unto C, De Vincentis A, Baiocchini A, Delle Monache M, Cecere R, Pellicelli AM, Giannelli V, Carotti S, Galati G, Gallo P, Valentini F, Del Nonno F, Rosati D, Morini S, Antonelli-Incalzi R, Picardi A.

Can J Gastroenterol Hepatol. 2018 Mar 14;2018:7564835. doi: 10.1155/2018/7564835. eCollection 2018.

8.

Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review.

Levi Sandri GB, Ettorre GM, Giannelli V, Colasanti M, Sciuto R, Pizzi G, Cianni R, D'Offizi G, Antonini M, Vennarecci G, Lucatelli P.

Transl Gastroenterol Hepatol. 2017 Nov 27;2:98. doi: 10.21037/tgh.2017.11.11. eCollection 2017. Review.

9.

Non selective beta blockers in cirrhosis.

Thalheimer U, Giannelli V, Francoz C, Maimone S.

J Hepatol. 2017 Dec;67(6):1342-1343. doi: 10.1016/j.jhep.2017.05.031. Epub 2017 Aug 5. No abstract available.

PMID:
28789879
10.

Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.

Pellicelli AM, Pace Palitti V, Vignally P, Ceccherini-Silberstein F, Siciliano M, Giannelli V, Moretti A, Tarquini P, Scifo G, Messina V, Ascione A, Izzi A, Marignani M, D'Ambrosio C, Fondacaro L, Ettorre GM, Ialongo P, Sacco R, Perno CF, Barbarini G; CLEO Group.

Liver Int. 2017 May;37(5):653-661. doi: 10.1111/liv.13288. Epub 2016 Dec 15.

PMID:
27782373
11.

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.

Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group.

J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17.

PMID:
26679249
12.

An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial.

Merli M, Lucidi C, Di Gregorio V, Lattanzi B, Giannelli V, Giusto M, Farcomeni A, Ceccarelli G, Falcone M, Riggio O, Venditti M.

Hepatology. 2016 May;63(5):1632-9. doi: 10.1002/hep.28332. Epub 2016 Jan 5.

PMID:
26529126
13.

Electronic Dietary Intake Assessment (e-DIA): Comparison of a Mobile Phone Digital Entry App for Dietary Data Collection With 24-Hour Dietary Recalls.

Rangan AM, O'Connor S, Giannelli V, Yap ML, Tang LM, Roy R, Louie JC, Hebden L, Kay J, Allman-Farinelli M.

JMIR Mhealth Uhealth. 2015 Oct 27;3(4):e98. doi: 10.2196/mhealth.4613.

14.

The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.

Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, Lattanzi B, Giusto M, Ceccarelli G, Farcomeni A, Riggio O, Venditti M.

PLoS One. 2015 May 21;10(5):e0127448. doi: 10.1371/journal.pone.0127448. eCollection 2015.

15.

Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry.

Giusto M, Lattanzi B, Albanese C, Galtieri A, Farcomeni A, Giannelli V, Lucidi C, Di Martino M, Catalano C, Merli M.

Eur J Gastroenterol Hepatol. 2015 Mar;27(3):328-34. doi: 10.1097/MEG.0000000000000274.

PMID:
25569567
16.

Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U.

World J Gastroenterol. 2014 Dec 7;20(45):16795-810. doi: 10.3748/wjg.v20.i45.16795. Review.

17.

Changes in nutritional status after liver transplantation.

Giusto M, Lattanzi B, Di Gregorio V, Giannelli V, Lucidi C, Merli M.

World J Gastroenterol. 2014 Aug 21;20(31):10682-90. doi: 10.3748/wjg.v20.i31.10682. Review.

18.

The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis.

Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, Riggio O, Venditti M.

Liver Int. 2015 Feb;35(2):362-9. doi: 10.1111/liv.12593. Epub 2014 Jun 4.

PMID:
24836902
19.

Beta-blockers in liver cirrhosis.

Giannelli V, Lattanzi B, Thalheimer U, Merli M.

Ann Gastroenterol. 2014;27(1):20-26. Review.

20.

Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.

Ponziani FR, ViganĂ² R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, Burra P, Miglioresi L, Merli M, Di Paolo D, Fagiuoli S, Gasbarrini A, Pompili M; AISF RECOLT-C Group, Belli L, Gerunda GE, Marino M, Montalti R, Di Benedetto F, De Ruvo N, Rigamonti C, Colombo M, Rossi G, Di Leo A, Lupo L, Memeo V, Bringiotti R, Zappimbulso M, Bitetto D, Vero V, Colpani M, Fornasiere E, Pinna AD, Morelli MC, Bertuzzo V, De Martin E, Senzolo M, Ettorre GM, Visco-Comandini U, Antonucci G, Angelico M, Tisone G, Giannelli V, Giusto M.

Dig Liver Dis. 2014 May;46(5):440-5. doi: 10.1016/j.dld.2014.01.157. Epub 2014 Mar 11.

PMID:
24635906
21.

Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.

Internullo M, Giannelli V, Sardo L, Antonaglia C, Villani T, Angelici E, Palange P.

Eur Rev Med Pharmacol Sci. 2014;18(2):190-3.

22.

Conversion from twice-daily to once-daily Tacrolimus administration in liver transplant patient: results of long term follow-up.

Giannelli V, Rossi M, Giusto M, Lucidi C, Lattanzi B, Ruffa A, Ginanni Corradini S, Mennini G, Melandro F, Lai Q, Berloco P, Merli M.

Eur Rev Med Pharmacol Sci. 2013 Oct;17(20):2718-20.

23.

Graft macrosteatosis and time of T-tube removal as risk factors for biliary strictures after liver transplantation.

Lattanzi B, Lai Q, Guglielmo N, Giannelli V, Merli M, Giusto M, Melandro F, Ginanni Corradini S, Mennini G, Berloco PB, Rossi M.

Clin Transplant. 2013 May-Jun;27(3):E332-8. doi: 10.1111/ctr.12124. Epub 2013 May 6.

PMID:
23647461
24.

Increased risk of cognitive impairment in cirrhotic patients with bacterial infections.

Merli M, Lucidi C, Pentassuglio I, Giannelli V, Giusto M, Di Gregorio V, Pasquale C, Nardelli S, Lattanzi B, Venditti M, Riggio O.

J Hepatol. 2013 Aug;59(2):243-50. doi: 10.1016/j.jhep.2013.03.012. Epub 2013 Mar 21.

PMID:
23523580
25.

Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.

Merli M, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V, Lattanzi B, Riggio O.

Metab Brain Dis. 2013 Jun;28(2):281-4. doi: 10.1007/s11011-012-9365-z. Epub 2012 Dec 7.

PMID:
23224378
26.

Metabolic syndrome and cardiovascular risk after liver transplantation: a single-center experience.

Iadevaia M, Giusto M, Giannelli V, Lai Q, Rossi M, Berloco P, Corradini SG, Merli M.

Transplant Proc. 2012 Sep;44(7):2005-6. doi: 10.1016/j.transproceed.2012.06.022.

PMID:
22974893
27.

Occurrence of chronic renal failure in liver transplantation: monitoring of pre- and posttransplantation renal function.

Umbro I, Tinti F, Piselli P, Fiacco F, Giannelli V, Di Natale V, Zavatto A, Merli M, Rossi M, Ginanni Corradini S, Poli L, Berloco PB, Mitterhofer AP.

Transplant Proc. 2012 Sep;44(7):1956-9. doi: 10.1016/j.transproceed.2012.06.012.

PMID:
22974881
28.

Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients.

Giannelli V, Giusto M, Farcomeni A, Ponziani FR, Pompili M, ViganĂ² R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, De Martin E, Miglioresi L, Di Paolo D, Fagiuoli S, Merli M; AISF RECOLT-C group study.

Transpl Int. 2012 Apr;25(4):448-54. doi: 10.1111/j.1432-2277.2012.01440.x. Epub 2012 Feb 21.

29.

Nutritional status and liver transplantation.

Merli M, Giusto M, Giannelli V, Lucidi C, Riggio O.

J Clin Exp Hepatol. 2011 Dec;1(3):190-8. doi: 10.1016/S0973-6883(11)60237-5. Epub 2012 Jan 2.

30.

Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

Merli M, Giannelli V, Gentili F, Giusto M, Simmaco M, Lionetto L, Corradini SG, Biliotti E, Attili AF, Rossi M, Taliani G.

Antivir Ther. 2011;16(6):879-85. doi: 10.3851/IMP1834.

PMID:
21900720
31.

Acute renal failure in liver transplant recipients: role of pretransplantation renal function and 1-year follow-up.

Tinti F, Umbro I, Giannelli V, Merli M, Ginanni Corradini S, Rossi M, Nofroni I, Poli L, Berloco PB, Mitterhofer AP.

Transplant Proc. 2011 May;43(4):1136-8. doi: 10.1016/j.transproceed.2011.02.042.

PMID:
21620071
32.

Cirrhotic patients are at risk for health care-associated bacterial infections.

Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M, Ridola L, Attili AF, Venditti M.

Clin Gastroenterol Hepatol. 2010 Nov;8(11):979-85. doi: 10.1016/j.cgh.2010.06.024. Epub 2010 Aug 12.

PMID:
20621200
33.

Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient.

Merli M, Di Menna S, Giusto M, Giannelli V, Lucidi C, Loria I, Ginanni Corradini S, Mennini G, Rossi M.

Transplant Proc. 2010 May;42(4):1322-4. doi: 10.1016/j.transproceed.2010.04.012.

PMID:
20534292
34.

Bone disorders in patients with chronic liver disease awaiting liver transplantation.

Loria I, Albanese C, Giusto M, Galtieri PA, Giannelli V, Lucidi C, Di Menna S, Pirazzi C, Corradini SG, Mennini G, Rossi M, Berloco P, Merli M.

Transplant Proc. 2010 May;42(4):1191-3. doi: 10.1016/j.transproceed.2010.03.096.

PMID:
20534258
35.

Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.

Douce G, Giannelli V, Pizza M, Lewis D, Everest P, Rappuoli R, Dougan G.

Infect Immun. 1999 Sep;67(9):4400-6.

36.

Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli.

Douce G, Giuliani MM, Giannelli V, Pizza MG, Rappuoli R, Dougan G.

Vaccine. 1998 Jul;16(11-12):1065-73.

PMID:
9682360
37.

Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.

Marchetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S, Covacci A, Massari P, Pagliaccia C, Manetti R, Telford JL, Douce G, Dougan G, Rappuoli R, Ghiara P.

Vaccine. 1998 Jan;16(1):33-7.

PMID:
9607006
38.
39.

Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop.

Giannelli V, Fontana MR, Giuliani MM, Guangcai D, Rappuoli R, Pizza M.

Infect Immun. 1997 Jan;65(1):331-4.

40.

Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin.

Magagnoli C, Manetti R, Fontana MR, Giannelli V, Giuliani MM, Rappuoli R, Pizza M.

Infect Immun. 1996 Dec;64(12):5434-8.

41.
42.

Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.

Fontana MR, Manetti R, Giannelli V, Magagnoli C, Marchini A, Olivieri R, Domenighini M, Rappuoli R, Pizza M.

Infect Immun. 1995 Jun;63(6):2356-60.

43.

A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit.

Pizza M, Fontana MR, Giuliani MM, Domenighini M, Magagnoli C, Giannelli V, Nucci D, Hol W, Manetti R, Rappuoli R.

J Exp Med. 1994 Dec 1;180(6):2147-53.

44.

Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis.

Pizza M, Domenighini M, Hol W, Giannelli V, Fontana MR, Giuliani MM, Magagnoli C, Peppoloni S, Manetti R, Rappuoli R.

Mol Microbiol. 1994 Oct;14(1):51-60.

PMID:
7830560
45.

[Ito's hypomelanosis. Ultrastructural investigation of the skin and the hair].

Calvieri S, Zampetti M, Grieco T, Giustini S, Corbo A, Giannelli V.

G Ital Dermatol Venereol. 1988 Nov;123(11):603-5. Italian. No abstract available.

PMID:
3254341
46.

[Preliminary results of the use of a microanalysis system of the hair in patients with trichothiodystrophy].

Calvieri S, Zampetti M, Corbo A, Giustini S, Rossi A, Giannelli V.

G Ital Dermatol Venereol. 1988 Nov;123(11):583-5. Italian. No abstract available.

PMID:
3254334
47.

[The hair in a case of biotinidase deficiency].

Calvieri S, Giustini S, Giannelli V, Carlesimo M, Amorosi B, Balestri P, Farnetani MA.

G Ital Dermatol Venereol. 1988 Nov;123(11):563-4. Italian. No abstract available.

PMID:
3254327
48.

Cimetidine and natural killer cell activity.

Calvieri S, Giannelli V, Zampetti M.

Clin Exp Dermatol. 1988 Jul;13(4):283. No abstract available.

PMID:
3246099
49.

[Statistic-clinical report on the 3 year-period from 1957 to 1959].

GIANNELLI V.

Rass Studi Psichiatr. 1960 Nov-Dec;49:1085-113. Italian. No abstract available.

PMID:
13705016
50.

[Clinical statistics referring to the triennial period from 1954 to 1956; statistical report & explanations].

GIANNELLI V.

Rass Studi Psichiatr. 1957 May-Jun;46(3):414-41. Italian. No abstract available.

PMID:
13466147

Supplemental Content

Loading ...
Support Center